MX2017000183A - Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. - Google Patents

Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.

Info

Publication number
MX2017000183A
MX2017000183A MX2017000183A MX2017000183A MX2017000183A MX 2017000183 A MX2017000183 A MX 2017000183A MX 2017000183 A MX2017000183 A MX 2017000183A MX 2017000183 A MX2017000183 A MX 2017000183A MX 2017000183 A MX2017000183 A MX 2017000183A
Authority
MX
Mexico
Prior art keywords
benzoxazinone
receptor modulators
mineralocorticoid receptor
formula
amides
Prior art date
Application number
MX2017000183A
Other languages
English (en)
Other versions
MX367404B (es
Inventor
O´MAHONY Gavin
Kossenjans Michael
Edman Karl
Kajanus Johan
Anders Hogner Carl
Cornwall Philip
Turner Andrew
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2017000183A publication Critical patent/MX2017000183A/es
Publication of MX367404B publication Critical patent/MX367404B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Se describen ciertos derivados de amidas de benzoxazinona de fórmula (I) o sus sales farmacéuticamente aceptables, que actúan como moduladores del receptor de mineralocorticoides (MR) que pueden reducir el estrés oxidativo en el endotelio y, por lo tanto, mejorar la función vascular, métodos para su potencial uso terapéutico, composiciones farmacéuticas que los contienen y procesos para preparar tales compuestos.
MX2017000183A 2014-06-30 2015-06-26 Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. MX367404B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (2)

Publication Number Publication Date
MX2017000183A true MX2017000183A (es) 2017-04-25
MX367404B MX367404B (es) 2019-08-20

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000183A MX367404B (es) 2014-06-30 2015-06-26 Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.

Country Status (25)

Country Link
US (2) US10017502B2 (es)
EP (1) EP3160948B1 (es)
JP (1) JP6368383B2 (es)
KR (1) KR102012222B1 (es)
CN (1) CN106536491B (es)
AR (1) AR101036A1 (es)
AU (1) AU2015282450C1 (es)
CA (1) CA2953655C (es)
CY (1) CY1121596T1 (es)
DK (1) DK3160948T3 (es)
EA (1) EA029518B1 (es)
ES (1) ES2707726T3 (es)
HR (1) HRP20190147T1 (es)
HU (1) HUE042370T2 (es)
LT (1) LT3160948T (es)
ME (1) ME03316B (es)
MX (1) MX367404B (es)
PL (1) PL3160948T3 (es)
PT (1) PT3160948T (es)
RS (1) RS58274B1 (es)
SI (1) SI3160948T1 (es)
TR (1) TR201900659T4 (es)
TW (1) TWI677498B (es)
UY (1) UY36195A (es)
WO (1) WO2016001631A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58274B1 (sr) * 2014-06-30 2019-03-29 Astrazeneca Ab Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora
EA202190226A1 (ru) 2018-07-19 2021-06-16 Астразенека Аб СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
JP2022530575A (ja) 2019-08-30 2022-06-30 アストラゼネカ・アクチエボラーグ ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
CA3222502A1 (en) 2021-06-15 2022-12-22 Lingyun Wu Benzoxazinone derivatives
WO2024015425A1 (en) 2022-07-14 2024-01-18 Fmc Corporation Herbicidal benzoxazines
WO2024047574A1 (en) 2022-09-01 2024-03-07 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528335A (ja) * 2001-04-23 2004-09-16 アストラゼネカ アクチボラグ 血管新生の治療に使用のベンゾオキサジノン誘導体
WO2004056820A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
EP1778233A1 (en) * 2004-07-14 2007-05-02 Ligand Pharmaceuticals, Inc. Intracellular receptor modulator compounds and methods
CN101365696A (zh) * 2004-07-28 2009-02-11 Irm责任有限公司 作为类固醇激素核受体调节剂的化合物和组合物
JP2009523701A (ja) 2005-12-28 2009-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
AP2527A (en) 2006-10-31 2012-12-06 Pfizer Prod Inc Pyrazoline compounds as mineralocorticoid receptorantagonists
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
AU2008230115A1 (en) 2007-03-23 2008-10-02 Merck Sharp & Dohme Corp. Mineralocorticoid receptor modulators
TWI444185B (zh) 2007-04-09 2014-07-11 Daiichi Sankyo Co Ltd 吡咯衍生物之阻轉異構物
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
AU2009260899B2 (en) * 2008-06-18 2012-02-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
AU2010222902B2 (en) 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
US20120022058A1 (en) 2009-04-10 2012-01-26 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
CA2798831A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
US8979337B2 (en) 2010-05-11 2015-03-17 Koninklijke Philips N.V. Lighting module
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
WO2012064631A1 (en) 2010-11-10 2012-05-18 Boehringer Ingelheim International Gmbh Pyridyl ureas as mineralocorticoid receptor antagonists
RS58274B1 (sr) * 2014-06-30 2019-03-29 Astrazeneca Ab Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora

Also Published As

Publication number Publication date
CA2953655A1 (en) 2016-01-07
CA2953655C (en) 2020-05-12
SI3160948T1 (sl) 2020-06-30
UY36195A (es) 2016-01-08
HRP20190147T1 (hr) 2019-03-22
US10017502B2 (en) 2018-07-10
TR201900659T4 (tr) 2019-02-21
TWI677498B (zh) 2019-11-21
EA029518B1 (ru) 2018-04-30
ES2707726T3 (es) 2019-04-04
EP3160948A1 (en) 2017-05-03
EA201790046A1 (ru) 2017-08-31
JP2017522300A (ja) 2017-08-10
AU2015282450C1 (en) 2018-09-20
AU2015282450B2 (en) 2018-05-10
US20150376170A1 (en) 2015-12-31
JP6368383B2 (ja) 2018-08-01
AR101036A1 (es) 2016-11-16
WO2016001631A1 (en) 2016-01-07
US20170217945A1 (en) 2017-08-03
KR20170021883A (ko) 2017-02-28
KR102012222B1 (ko) 2019-10-21
TW201613909A (en) 2016-04-16
CY1121596T1 (el) 2020-05-29
DK3160948T3 (en) 2019-02-18
CN106536491B (zh) 2018-12-18
AU2015282450A1 (en) 2017-02-02
HUE042370T2 (hu) 2019-06-28
ME03316B (me) 2019-10-20
US9394291B2 (en) 2016-07-19
CN106536491A (zh) 2017-03-22
PL3160948T3 (pl) 2019-04-30
EP3160948B1 (en) 2018-10-24
PT3160948T (pt) 2019-02-01
LT3160948T (lt) 2019-02-11
RS58274B1 (sr) 2019-03-29
MX367404B (es) 2019-08-20

Similar Documents

Publication Publication Date Title
MX367404B (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
NZ727185A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726608A (en) Phosphatidylinositol 3-kinase inhibitors
MY191590A (en) 9h-pyrrolo-dipyridine derivatives
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
NZ726360A (en) Phosphatidylinositol 3-kinase inhibitors
MD20160136A2 (ro) Compuşi dihidroizochinolinonici substituiţi
TW201613895A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
TW201613864A (en) Novel compounds
IN2013MU03577A (es)
CR20160527A (es) Derivados de carboxamida
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
TR201819805T4 (tr) Flavaglin türevleri̇.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
TW201613921A (en) Serine derivatives as ghrelin receptor agonists
IN2013MU03838A (es)

Legal Events

Date Code Title Description
FG Grant or registration